drugset / Trial / NCT04583488
Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label, non-randomized, uncontrolled Phase 1 study of intraperitoneal docetaxel in combination with systemic mFOLFOX6 for patients who have gastric cancer with gross peritoneal carcinomatosis (GC-PC).
Timeline
- Start
- 2020-11-01
- Primary completion
- 2024-08-06
- Completion
- 2024-08-06
Outcome
Outcome not reported
Stopped: “PI left institution”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 25 mg/m2 | Other |
| Subject | Docetaxel | Small molecule | 35 mg/m2 | Other |
| Subject | Docetaxel | Small molecule | 45 mg/m2 | Other |